ALDR News and Press, Alder BioPharmaceuticals Inc. From 05/14/19

BOTHELL, Wash., May 14, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview a...

A new analysis of patient-reported outcomes from a Phase 3 clinical trial, PROMISE-2 , evaluating Alder BioPharmaceuticals' (NASDAQ: ALDR ) migraine prevention med eptinezumab confirmed its treatment benefit. The data are being presented at the American Academy of Neurology Annual Meeting...

- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two treatments with eptinezumab - - Study represents first time most ...

BOTHELL, Wash., May 06, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new efficacy data highlighting consistency of early migraine preventi...

Alder Biopharmaceuticals, Inc. (ALDR) Q1 2019 Earnings Conference Call May 02, 2019, 17:00 ET Company Participants Michael Horowicz - Stern Investor Relations Bob Azelby - CEO Paul Streck - CMO Carlos Campoy - CFO Conference Call Participants Charles Duncan - Cantor Fitzg...

Alder Bio (NASDAQ: ALDR ): Q1 GAAP EPS of -$1.63 misses by $0.72 . More news on: Alder BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 -                             - Acute study planned for potential eptinezumab label expans...

BOTHELL, Wash., April 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2019 financial and operating ...

Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Arrowhead Pharmaceuticals ( ARWR ) - The company announced that dosing has begun in a new triple combination cohort utilizing JNJ-3989 plus additional undisclosed agents in the ongoing phase 1/2 study in patients with chronic hepatitis B virus. As a result of opening this new cohort, Arrowhe...